FinAd research workflow
finad.shardingsmeet.com
LoginSign up
Research mode active. Personalized investment actions require suitability and advisor approval.

FinAd is in research and education mode by default. Outputs are probabilistic research signals, not guaranteed returns or personalized investment advice.

Personalized investment recommendations for Indian securities must be reviewed and approved by a SEBI-registered investment adviser or authorized expert workflow before being shown as advice.

NSE:SUNPHARMA

Sun Pharmaceutical Industries

Healthcare / Healthcare. Analysis combines daily candles, derived indicators, fundamentals, news intelligence, and review-gated recommendations.

quality
68
momentum
84
valuation
36
news
50
liquidity
70
risk
53

Recommendations by horizon

NSE:SUNPHARMA / 20D

Sun Pharmaceutical Industries

momentum-trend
HOLDResearch mode
Confidence66/100
Risk53/100
Why this is ranked here
  • Trend score is supported by moving-average alignment and relative strength.
  • Quality score benefits from return ratios, growth, margin profile, and balance-sheet discipline.
  • No promoter pledge is present in the sample fundamental snapshot.
What can go wrong
  • Momentum may be extended; entry timing requires discipline.
  • All signals are probabilistic and require SEBI-registered advisor review before personalized advice.
Entry: 979.95 - 1007.51 around confirmed liquidity
Invalidation: 817.58
Freshness: 2026-05-07
Model: finad-explainable-v0.1.0
NSE:SUNPHARMA / 6M

Sun Pharmaceutical Industries

balanced-ai-blend
HOLDResearch mode
Confidence58/100
Risk53/100
Why this is ranked here
  • Trend score is supported by moving-average alignment and relative strength.
  • Quality score benefits from return ratios, growth, margin profile, and balance-sheet discipline.
  • No promoter pledge is present in the sample fundamental snapshot.
What can go wrong
  • Momentum may be extended; entry timing requires discipline.
  • All signals are probabilistic and require SEBI-registered advisor review before personalized advice.
Entry: 969.92 - 1007.51 around confirmed liquidity
Invalidation: 817.58
Freshness: 2026-05-07
Model: finad-explainable-v0.1.0
NSE:SUNPHARMA / MULTI_YEAR

Sun Pharmaceutical Industries

quality-compounder
HOLDAdvisor approved
Confidence60/100
Risk53/100
Why this is ranked here
  • Trend score is supported by moving-average alignment and relative strength.
  • Quality score benefits from return ratios, growth, margin profile, and balance-sheet discipline.
  • No promoter pledge is present in the sample fundamental snapshot.
What can go wrong
  • Momentum may be extended; entry timing requires discipline.
  • All signals are probabilistic and require SEBI-registered advisor review before personalized advice.
Entry: 969.92 - 1007.51 around confirmed liquidity
Invalidation: 817.58
Freshness: 2026-05-07
Model: finad-explainable-v0.1.0